MedDataX Logo

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

NCT ID: NCT00276146

Last Updated: 2013-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the benefits as well as side effects of giving drugs called dipyridamole and magnesium to patients with sickle cell anemia (SCA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vaso-occlusive episodes are the most common problem experienced by patients with SCA and the most frequent reason for hospital admissions as well as visits to the clinic and emergency department. Many cellular, humoral, and vascular factors influence the initiation and propagation of vaso-occlusion by sickle cells. Among these is the tendency of sickle cells (SS RBC) to become dehydrated with accompanying increase in the hemoglobin (Hb) concentration. Since sickle hemoglobin (Hb S) concentration controls the rate of polymerization, cellular dehydration plays a key role in sickle cell pathology.

Two separate but interdependent cation transport mechanisms affect sickle cell hydration, the first involving abnormal KCl cotransport (KCC), and the second a sickle-induced (SI) passive leak which permits the influx of calcium ions (Ca++) that activates the Gardos pathway, a Ca++-dependent K channel. Early investigations aimed at inhibiting KCC with magnesium (Mg) and the Gardos pathway with clotrimazole met with partial success. We have recently shown in vitro that dipyridamole also inhibits the SI pathway. Strategies designed to block the formation of these dense, dehydrated cells would offer important therapeutic options that might decrease the number and severity of the vaso-occlusive episodes in patients. Drawing on the information gained from two decades of research on cation transport in SS RBC, including the unique discovery made at this Center that dipyridamole inhibits the SI cation leak, we now propose a study of combined therapy using two transport inhibitors aimed at reducing SS RBC dehydration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia, Sickle Cell

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

dipyridamole magnesium sickle cell anemia red blood cells

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oral dipyridamole, oral magnesium, or a combination of both

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with homozygous sickle cell (Hb SS) confirmed by hemoglobin electrophoresis or HPLC
* Patients with adequate cardiac, renal, and liver function
* Patients with baseline fetal hemoglobin (Hb F) level of 10% or less
* Patients with at least 6% dense cells or higher at initial screening visit
* Patients with no history of coronary heart disease
* Patients with normal baseline ECG
* Patients with no history of hypotension or hypotensive episodes

Exclusion Criteria

* Patients who are pregnant, trying to become pregnant, or breast feeding
* Patients who are on a chronic transfusion program
* Patients who are unable to take oral medications
* Patients who have significant cardiac, renal, or liver dysfunction
* Patients who are on hydroxyurea
* Patients who have a fetal hemoglobin (Hgb F) level of greater than 10%, or have less than 6% dense cell on initial screen
* Patients who are taking a supplement which contains magnesium
* Patients who are taking aspirin, ibuprofen on a daily basis, or anti-coagulant such as Coumadin on a daily basis
* Patients who have a known underlying coagulopathy (acquired or congenital) or have prolonged PT or PTT at the time of initial screen
* Patients who have had a hypersensitivity to either of the study medications
* Patients who are taking any other study medication(s). Patients will not be excluded if they are on penicillin prophylaxis or folic acid, or use ibuprofen intermittently
* Patients taking tetracycline or sodium polystyrene sulfonate
* Patients on concomitant medications and other therapy must have a wash out period prior to study entry and/or study drug dosing
* Patients with abnormal baseline ECG
* Patients with a history of hypotension or hypotensive episodes
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Children's Hospital Medical Center, Cincinnati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Karen Kalinyak, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital Medical Center, Cincinnati

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.cincinnatichildrens.org/svc/alpha/b/blood/programs/sickle-cell/

Sickle Cell Center at Cincinnati Children's Hospital Medical Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U54HL070871

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CCHMC 03-7-41

Identifier Type: -

Identifier Source: org_study_id